New pill could tame stubborn hives

NCT ID NCT06865651

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This study tests a new drug called remibrutinib (a tablet) against a placebo in 44 adults with chronic hives (either spontaneous or triggered by things like pressure or cold). The goal is to see if it reduces symptoms like itching and burning, and how it works in the body. Participants take the drug or placebo for 12 weeks, and researchers track symptom control and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: remibrutinib (a tablet drug)
What this could lead to: If it works, this could point toward a new treatment option for people with chronic hives that are not well controlled by current antihistamines.
What could go wrong: This is an early phase 2 study with only 44 participants, so results may not apply to everyone. The drug may not prove more effective than placebo, and side effects are still being explored.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

allergic urticaria cholinergic urticaria chronic idiopathic urticaria Chronic Inducible Urticaria chronic urticaria cold urticaria familial dermatographia physical urticaria solar urticaria urticaria, aquagenic urticaria, familial localized heat Urticaria, Solar

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC URTICARIA (CU): CHRONIC INDUCIBLE URTICARIA (CINDU) AND CHRONIC SPONTANEOUS URTICARIA (CSU)

Contacts and locations

Locations

Endeavor Health
RECRUITING

Glenview, Illinois, 60077, United States
Novartis Investigative Site
RECRUITING

Grenoble, 38043, France
Novartis Investigative Site
RECRUITING

Montpellier, 34295, France
Novartis Investigative Site
RECRUITING

Paris, 75970, France
Novartis Investigative Site
RECRUITING

Pierre-Bénite, 69495, France
Novartis Investigative Site
RECRUITING

Dresden, Saxony, 01307, Germany
Novartis Investigative Site
RECRUITING

Berlin, 13353, Germany
Novartis Investigative Site
WITHDRAWN

Mainz, 55131, Germany
Novartis Investigative Site
RECRUITING

Tübingen, 72076, Germany
Novartis Investigative Site
RECRUITING

Poznan, 61-731, Poland
Novartis Investigative Site
WITHDRAWN

Rzeszów, 35 055, Poland
Novartis Investigative Site
WITHDRAWN

Warsaw, 02-962, Poland
Novartis Investigative Site
RECRUITING

Barcelona, Catalonia, 08003, Spain
Novartis Investigative Site
RECRUITING

Pamplona, Navarre, 31008, Spain
Novartis Investigative Site
RECRUITING

Alicante, 03010, Spain
Novartis Investigative Site
RECRUITING

Madrid, 28006, Spain
Ziaderm Research LLC
RECRUITING

North Miami Beach, Florida, 33162, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.